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Abstract
Background: Pulmonary arterial hypertension (PAH) is a severe complication of systemic sclerosis (SSc), associated
with a progressive elevation in pulmonary vascular resistance and subsequent right heart failure and death. Due to
unspecific symptoms, the diagnosis of PAH is often delayed. On this basis, it is of great value to improve current
diagnostic methods and develop new strategies for evaluating patients with suspected PAH. Interleukin-32 (IL-32) is
a proinflammatory cytokine expressed in damaged vascular cells, and the present study aimed to assess if this
cytokine could be a new biomarker of PAH during SSc.
Methods: The IL-32 expression was evaluated in the sera and skin samples of 18 SSc-PAH patients, 21 SSc patients
without PAH, 15 patients with idiopathic PAH (iPAH) and 14 healthy controls (HCs), by enzyme-linked
immunosorbent assay (ELISA) and immunohistochemistry (IHC). Receiver-operating characteristic (ROC) curves were
performed to evaluate the cut-off of IL-32 in identifying patients with PAH. Furthermore, in SSc patients, correlation
analyses were performed between IL-32 sera levels and mean pulmonary artery pressure (mPAP) evaluated by right
heart catheterization (RHC) and systolic pulmonary artery pressure (sPAP), obtained by echocardiography.
Additionally, the number of skin IL-32+ cells was correlated with modified Rodnan skin score (mRSS).
Results: In SSc-PAH patients, IL-32 sera levels were significantly higher when compared with SSc patients without
PAH and patients affected by iPAH. The analysis of ROC curve showed that IL-32 sera levels above 11.12 pg/ml were
able to predict patients with PAH (sensitivity = 90%, specificity = 100%). Furthermore, the IL-32 sera levels of patients
with SSc correlated with both mPAP and sPAP. In the skin derived from SSc-PAH patients, the number of IL-32+
cells was significantly increased when compared with the skin derived from SSc patients without PAH, correlating
with the mRSS.
Conclusion: Our study suggested that sera determination of IL-32 may be a promising approach to evaluate the
presence of PAH in SSc patients and together with longitudinal future studies could help to increase the
understanding how these biomarkers mirror the vascular changes and the inflammatory process during SSc.
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Background
Systemic sclerosis (SSc) is a systemic autoimmune dis-
ease characterised by microvascular damage and pro-
gressive fibrotic manifestations of the skin and internal
organs [1–4], classified in two different subsets, display-
ing different clinical patterns and outcomes: limited
cutaneous (lcSSc) and diffuse cutaneous (dcSSc). Cardio-
pulmonary involvement is the most common cause of
morbidity and mortality in those patients [5]. According
to the last clinical classification of pulmonary arterial
hypertension (PAH), pulmonary hypertension can occur
due to pure vascular involvement (WHO Group 1), sec-
ondary to SSc-interstitial lung disease (WHO Group 2)
and secondary to cardiac involvement (post-capillary
pulmonary hypertension, WHO Group 3) in those pa-
tients [6]. Isolated PAH (in the absence of lung fibrosis)
is one of the more severe complications of SSc, associ-
ated with a very high mortality rate, [7]. It has been re-
ported that the 1-year survival rates for SSc-PAH
patients range from 50 to 81% [8], having about a three-
fold increase in the mortality risk when compared with
iPAH [9]. Thus, an early diagnosis is essential, because
the late referral to cardiologists, when the symptoms of
right heart dysfunction are already present, predicts a
worse survival [10, 11]. However, early and accurate
diagnosis of PAH is a clinical challenge, needing right
heart catheterization (RHC), an invasive test which have
to be performed in those patients at increased risk of
PAH, following echocardiographic results and additional
criteria [12–14]. In this context, the availability of suit-
able diagnostic biomarkers for an early identification of
SSc-PAH patients, still in asymptomatic phase, may sig-
nificantly impact patient’s survival. A large number of
circulating biomarkers have been investigated in the last
years, but so far, only B-type natriuretic peptide (BNP)
and N-terminal proBNP (NT-proBNP) are routinely
used in the clinical setting, since being associated with
the severity of heart involvement [15, 16].
It is well known that pulmonary arteries display
complex structural and functional changes during PAH
and pulmonary endothelial cells’ (ECs) dysfunction plays
a crucial role in disease progression, leading to vascular
defects observed in SSc patients [17–22]. Hyper-
proliferative ECs may contribute to pulmonary arterial
remodelling, leading to the obliteration of vascular
lumen [23]. IL-32, a proinflammatory cytokine, originally
described as a transcript termed NK4, is considered a
key regulator molecule of EC activities [24, 25]. Al-
though 9 different isoforms are described according to
varying mRNA splicing [26], IL-32α, IL32-β and IL-32γ
are the most prominent isoforms [24]. Biologically, IL-32
resembles the activity of another cytokine of the same
family, the IL-33 [27], largely activated in damaged ECs
of SSc [28] and over-expressed in arteries of giant cell
arteritis patients [29, 30], acting as a “danger signal/alar-
min” molecule. The EC production of IL-32 is enhanced
by various inflammatory stimuli, such as IL-1b, IL-1a,
IL-6, and IL-8, and among them IL-1 and IL-8 are po-
tent promoters of angiogenesis [24, 31]. Of interest, IL-
32 has been identified in the abnormal ECs, populating
the plexiform lesions in the lungs of patients with iPAH
[25], and probably involved in both activation and prolif-
eration of these ECs. Increased IL-32 levels have been
found associated with [25, 32, 33] activity and/or severity
of Behcet’s disease [34], systemic lupus erythematosus
and atopic dermatitis [35, 36]. Presently, the role of IL-
32 in SSc is still unknown; thus, we assessed the expres-
sion of IL-32 in the sera of SSc patients with PAH
(WHO Group 1) and compared these values with those
from SSc patients without PH and patients with iPAH.
In addition, we correlated the IL-32 sera levels with the
mean pulmonary artery pressure (mPAP) assessed by
RHC and the values of systolic pulmonary artery
pressure (sPAP), obtained by echocardiography, to
understand if IL-32 may be considered an additional
non-invasive screening tool for SSc patients with signs
and symptoms of PAH.
The pathogenic mechanisms of experimental PAH
largely mirror what described in SSc vascular defects
[17, 19–22], and on these bases, we searched for IL-32
expression in the skin samples of our SSc patients.
Finally, we correlated the number of IL-32+ cells in the
affected skin with the modified Rodnan skin score
(mRSS), a surrogate for disease activity, severity and
mortality in patients with dcSSc [37].
Materials and methods
Patients and controls
Eighteen SSc patients with WHO group 1 PAH [6], con-
secutively selected during the diagnostic RHC, and 21
patients with SSc [38] without PAH, selected among
those patients consecutively admitted in our outpatient
clinics, who underwent sPAP evaluation, showing a nor-
mal sPAP associated with no sign or symptom referred
to heart involvement, in the context of their routinely
clinical assessment, were enrolled for this cross-sectional
study. All patients fulfilled the 2013 classification criteria
for SSc [39]. The diagnosis of PAH was confirmed ac-
cording to the European guidelines [14]. Fifteen patients
with iPAH and 14 HCs were also evaluated as controls.
For this study, sera of the SSc-PAH patients and sera of
iPAH patients, collected at the time of diagnostic RHC,
were matched with the sera of SSc patients without
PAH, and with the sera of HCs. Patients with infections,
malignant diseases or other diseases, which could be
possibly associated with increases of IL-32 sera levels,
were excluded. SSc patients without PAH, needing pros-
tanoids, calcium-channel blockers, phosphodiestererase-
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5 inhibitors and endothelin-1 receptor antagonists, were
excluded from this study. Samples from SSc-PAH
patients were collected before starting vasoactive therap-
ies. All patients were evaluated by echocardiography, the
initial non-invasive test for the screening of pulmonary
hypertension [40, 41]. sPAP was estimated from peak
tricuspid regurgitation jet velocities according to the
equation: sPAP = 4 (V)2 + RA pressure, where V is the
peak velocity (in metres per second) of TRV, as previ-
ously performed [42].
RHC
RHC was performed via femoral venous access, with
zero reference levelled at mid chest in the supine pos-
ition. Parameters concerning pulmonary circulation were
measured as follows: mean right atrium pressure, right
ventricle pressure, pulmonary artery pressure and wedge
pressure obtained after catheter balloon inflation at the
end of expiration. Cardiac output was measured using
the thermodilution technique, through a thermistor-
tipped Swan-Ganz catheter, or the Fick technique in
patients with severe tricuspid regurgitation. Pulmonary
vascular resistance was calculated as (mPAP-PAWP)/
CO.
Enzyme-linked immunosorbent assay
Sera levels of IL-32 were determined by commercial
human ELISA using Human IL-32 ELISA (R&D, USA),
according to the manufacturer’s protocol. All experi-
ments were performed in duplicate.
Skin biopsies
Full-thickness biopsy samples, 2 × 0.5 cm, isolated from
excisional biopsy, were obtained from clinically involved
skin of one third of the distal forearm of patients af-
fected by SSc. Skin with a mRSS of ≥ 1 was considered
to be clinically involved [43]. Skin samples obtained
from donors, matched for age and gender, undergoing a
surgical treatment for trauma of arms, were used as
controls. Both skin and blood samples derived from pa-
tients undergoing RHC were collected at the time of
catheterization.
Immunohistochemistry
Each biopsy sample was fixed in 10% buffered formalin,
dehydrated in graded alcohol series, and embedded in
paraffin. Skin sections (thickness 3 μm) were deparaffi-
nised, treated with endogenous peroxidase blocking
(Dako, USA) and then with Dako Protein block (Dako,
USA) to block non-specific binding. After blocking, sec-
tions were incubated with anti-IL-32 antibody (AbCam,
UK). Visualisation of the primary antibodies was per-
formed using EnVision Flex/HRP and DAB (diamino-
benzidine) (both Dako, USA). No immunohistochemical
staining was noted in negative control samples where
the primary antibody was omitted. Sections were exam-
ined and photographed under light microscope (Olym-
pus BX53). The number of positive cells was counted by
two pathologists, blinded to tissue source and expressed
as the mean of two observations for each sample. Results
were reported as the median (range) of number of
positive cells per microscopic field, considering the non-
parametric distribution.
Ethics committee approval
The local ethics committee approved the study protocol
(ASL1 Avezzano Sulmona L’Aquila, L’Aquila, Italy,
protocol number #1039, Università degli Studi di ROMA
“La Sapienza” protocol number #1011), which has been
performed according to the Good Clinical Practice
guidelines and the Declaration of Helsinki.
Statistical analysis
According to data distribution, results were presented as
mean and standard deviation (SD) or median and inter-
quartile range (IQR) as appropriate, and consequently,
parametric or non-parametric t tests were used to com-
pare these variables. Spearman’s correlation was used to
correlate IL-32 with sPAP. Furthermore, the receiver-
operating characteristic (ROC) curves were performed to
evaluate the predictivity of IL-32 sera levels in identify-
ing patients with PAH. The best cut-off for ROC curves
was calculated by the Youden’s index. Due to the
relatively simple study design, few missing data were
managed by exclusion of these from analyses. Statistical
significance was expressed by a p value < 0.05. GraphPad
Prism 5.0 software and Statistics Package for Social
Sciences (SPSS version 17.0, SPSS Inc) were used for
statistical analyses.
Results
Baseline characteristics of the study population
Eighteen SSc-PAH patients, 21 SSc patients without
PAH, 15 patients with iPAH and 14 HCs were analysed.
Demographic and clinical characteristics of our cohorts
are summarised in Table 1.
The mean age of SSc-PAH patients was 69.8 ± 8.0
years; 16 patients were Caucasian female. The mean age
of SSc patients without PAH was 60.5 ± 9.3 years; 18 pa-
tients were Caucasian female. The mean value of systolic
pulmonary artery pressure (sPAP) estimated by Doppler
echocardiography was 73.1 ± 16.6 in SSc-PAH patients,
23.3 ± 4.4 in SSc patients without PAH, and 68.7 ± 20.5
in patients with iPAH. Among the SSc-PAH patients, 13
patients showed the dcSSc form and 5 showed the lcSSc
form, and among the SSc patients without PAH, 14 pa-
tients were classified as dcSSc and 7 as lcSSc. The mean
value of mRSS of dcSSc-PAH patients was 16.8 ± 2.4; the
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mean value of mRSS of dcSSc patients without PAH was
10.6 ± 7.1.
IL-32 sera levels in patients with SSc
Figure 1a shows that the IL-32 sera levels were signifi-
cantly higher in SSc-PAH patients, when compared
with SSc patients without PAH [99.9 pg/ml (55.4–
185.6) in SSc-PAH patients vs 0 pg/ml (0–9.9) in SSc
patients without PAH; p < 0.0001]. Additionally, the IL-
32 sera levels in SSc-PAH patients were significantly
higher when compared with patients affected by iPAH
[99.9 pg/ml (55.4–185.6) in SSc-PAH patients vs 62.1
pg/ml (0–197.8) in patients with iPAH; p = 0.03]. As
reported in Fig. 1b, we did not found any significant
difference in IL-32 sera levels when stratifying the
patients according to disease subsets [118.1 pg/ml
(74.3–147.5) in lcSSc-PAH patients vs 91.6 pg/ml
(55.4–185.6) in dcSSc-PAH patients, p = 0.4; 0 pg/ml
(0–7.2) in lcSSc patients without PAH vs 3.1 pg/ml (0–
9.9) in dcSSc patients without PAH, p = 0.3].
Table 1 Baseline characteristics of the study population
SSc-PAH SSc Idiopathic PAH Healthy control
N 18 21 15 14
Men/woman (N of patients) 2/16 3/18 5/10 3/11
Disease duration (years ± SD 21.1 ± 7.6 19.1 ± 9.0 20.0 ± 10
Age (mean, years ± SD) 69.8 ± 8.0 60.5 ± 9.3 62.5 ± 14.6 63.7 ± 10.1
lcSSc/dcSSc (N of patients) 5/13 7/14
ACA/Scl70 (N of patients) 5/13 7/14
Digital ulcers (N of patients) 2 1
sPAP eco 73.1 ± 16.6 23.3 ± 4.4 68.7 ± 20.5
mPAP RHC 43.0 ± 10.6 49.9 ± 21.0
mRSS in dcSSc (mean ± SD) 16.8 ± 2.4 10.6 ± 7.1
mRSS in lcSSc (mean ± SD) 3.6 ± 2.5 3.9 ± 2.3
Prostanoid Not Not Not Not
Calcium-channel blockers Not Not Not Not
Phosphodiestererase-5 inhibitors Not Not Not Not
Endothelin-1 receptors antagonists Not Not Not Not
Vasoactive therapies Not Not Not Not
ACA anti-centromere antibodies, dcSSc diffuse cutaneous SSc, lcSSc limited cutaneous SSc, mPAP RHC mean pulmonary artery pressure measured by RHC, mRSS
modified Rodnan skin score, N number, PAH Pulmonary arterial hypertension, RHC right heart catheterization, SD standard deviation, sPAP eco systolic pulmonary
artery pressure measured by echocardiography, SSc systemic sclerosis
Fig. 1 IL-32 sera levels. a ELISA assays. In SSc-PAH patients, IL-32 sera levels are significantly higher when compared with SSc patients without
PAH (*p = 0.03; ***p≤ 0.0001). b ELISA assays stratifying the SSc patients according to disease subset. No difference in IL-32 sera levels is assessed,
stratifying the patients in limited cutaneous (lcSSc) subset and diffuse cutaneous (dcSSc) subset. Independent of the diseases subset, in SSc-PAH
patients, IL-32 sera levels are significantly increased when compared to SSc patients without PAH (**p = 0.002; ***p < 0.001)
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Sensitivity and specificity of IL-32 as biomarker to identify
SSc-PAH patients
The area under the ROC curve resulted to be 0.950
(95% CI 0.889–1.000, p < 0.0001) for IL-32 sera levels. By
analysis of the ROC curve, we assessed that the best cut-
off for IL-32 sera levels was 11.12 pg/ml, to predict
patients with PAH, providing a sensitivity of 90% and a
specificity of 100% (Fig. 2).
Correlations between IL-32 sera levels and mPAP
evaluated by RHC in SSc patients
Figure 3a shows a positive correlation between IL-32
levels obtained from SSc patients undergoing RHC, to
confirm PAH, and their mPAP measures [Spearman r =
0.37 (CI − 0.01 to 0.66), p = 0.02; linear regression r2 =
0.13, p = 0.02].
Correlations between IL-32 sera levels and sPAP
evaluated by Doppler echocardiography in SSc patients
Figure 3b shows a positive correlation between IL-32
sera levels of SSc patients and sPAP measures [Spear-
man r = 0.68 (CI 0.46–0.83), p < 0.0001; linear regression
r2 = 0.7, p < 0.0001].
IL-32-positive cells in the skin of patients with SSc
Figure 4 shows that IL-32 was expressed in keratino-
cytes, vascular cells and fibroblasts present in the derma.
The number of IL-32+ cells was significantly increased
in skin derived from SSc patients, when compared with
HCs-skin [number of IL-32+ cells in SSc skin 55 (16–
152) vs number of IL-32+ cells in HCs skin 19.5 (10–
50); p = 0.0001]. Among SSc patients, the IL-32+ cells
were significantly increased in the subset of patients with
PAH [number of IL-32+ cells in skin of SSc-PAH
patients 110 (55–152) vs number of IL-32+ cells in skin
of SSc patients 30 (16–60); p < 0.0001].
Correlations between IL-32+ cells in the skin of dcSSc
patients and mRSS
The number of IL-32+ cells in the skin of dcSSc patients
directly correlated with values of mRSS (Fig. 5) [Spear-
man r = 0.42 (CI 0.04–0.70), p = 0.02; linear regression
r2 = 0.12, p = 0.02].
Discussion
Our study suggests that IL-32, already identified in the
lung of iPAH patients [25], may be considered a poten-
tial biomarker to identify SSc patients with WHO group
1 PAH. We enrolled 21 SSc-PAH patients, 13 showing
the diffuse form and 5 the limited form of the disease.
Although, it has been generally accepted that PAH is
more common in lcSSc [7, 44, 45], recent evidence failed
to confirm these previous data, showing that PAH may
also affect dcSSc patients at least as frequently as the
limited form [46, 47].
We observed that IL-32 sera levels were higher in pa-
tients with PAH; on the contrary, those levels were quite
undetectable in SSc patients without PAH and HCs,
confirming the relevance of this cytokine in highlighting
the presence of WHO group 1 PAH. It has been
reported that IL-32 may play a key role in the vascular
alterations occurring during iPAH and showing a pro-
inflammatory effect in several inflammatory and auto-
immune diseases [25, 33–35]. In fact, IL-32 has been
described in the abnormal ECs, populating the plexiform
lesions in the lungs from iPAH patients [25], and its pro-
duction seems to promote the leukocyte recruitment via
the production of pro-inflammatory cytokines, such as
tumour necrosis factor-α (TNF-α), IL-1β, IL-6 and IL-8
[27], all contributing to EC injury [24, 25, 31]. Further-
more, IL-32 may play an additional role, modulating
activation and proliferation of ECs during the angiogen-
esis [25], although conflicting results are present in
literature [48]. IL-32 may modulate the VEGF expression
during cancer, promoting the pro-angiogenic program
[25, 49], while in human bronchial epithelial cells, IL-32
appears to suppress the pro-angiogenic signals [48]. In
our setting, the increase of IL-32 levels, observed only in
the patients with PAH, should be referred to the specific
EC damage, associated with PAH, more than a disturb-
ance of the immune-homeostasis, as reported for other
autoimmune diseases [32, 33]. Although it is still un-
known what isoform is associated with the organisation
of plexiform lesions, during iPAH, one study suggested
that IL-32γ may be the main isoform, involved in the
Fig. 2 Receiver operating characteristic (ROC) curves. ROC curves.
The area under the ROC curve resulted to be 0.950 (95% CI 0.889–
1.000, p < 0.0001) for IL-32 sera levels. The analysis of ROC curve
shows that the best cut-off for IL-32 sera levels is 11.12 pg/ml
(sensitivity = 90%; specificity = 100%)
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angiogenic process [25]. Nine different IL-32 isoforms
have been identified [26], and among them, IL-32α, IL-
32β and IL-32γ are the most representative forms [26].
In this study, mirroring what was already done in others’
papers measuring the levels of IL-32 as biomarker of dis-
eases, we used ELISA kit to be able to recognise the
three main isoforms (α, β and γ), as reported by others
[34, 50, 51]. Considering that the main goal of our work
was to assess the possible use of IL-32 as a new and rele-
vant biomarker to discriminate those SSc patients at
higher risk of PAH, we did not analysed the specific role
of any isoform. Surely, further studies are needed to
establish the pathogenic role of each isoform in SSc
patients developing PAH.
At present, no specific biomarker for PAH has been
identified so far, although a wide variety of molecules
have been explored [14], all of them lacking a significant
specificity to identify patients to be referred to cardiolo-
gists for performing RHC and/or to follow up patients
with already confirmed PAH. In our study, we identified
the specific cut-off (IL-32 sera levels of 11.12 pg/ml,
sensitivity = 90%, specificity = 100%), which is able to
Fig. 3 Correlations between IL-32 sera levels and both mPAP and sPAP. a The correlation analysis of IL-32 sera levels and mPAP shows that the
IL-32 sera levels of patients with SSc correlate with mPAP measures (r2 = 0.13; p = 0.02). b The correlation analysis of IL-32 sera levels and sPAP
shows that the IL-32 sera levels of patients with SSc correlate with sPAP measures (r2 = 0.7; p < 0.0001)
Fig. 4 IL-32 expression in the skin of SSc patients. a–c IHC of IL-32 in skin derived from HCs (a), SSc patients (b) and SSc-PAH patients (c). IL-32
was expressed in keratinocytes (arrow), vascular cells (arrowhead) and fibroblasts (*). Original magnification × 25. Negative controls were obtained
by omitting the primary antibody. d Quantification of the number of IL-32+ cells in HCs and SSc patients. The number of IL-32+ cells are
significantly increased in SSc patients when compared to SSc (***p = 0.0001). e Quantification of the number of IL-32+ cells in 14 HCs, 21 SSc
patients without PAH and 18 SSc patients with PAH. In SSc-PAH patients, the number of IL-32+ cells is significantly increased when compared to
SSc patients without PAH. Any dot plot is representative of the median cells count per 2 section for each patient (*p = 0.02; ***p < 0.0001)
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discriminate SSc patients at higher risk of WHO group 1
PAH. Although this study retrospectively assessed a rela-
tively low number of patients, the strong sensitivity and
specificity observed in our work suggest that IL-32 sera
levels may emerge as a new specific biomarker, helpful
for an accurate screening of SSc patients with suspected
WHO group 1 PAH, being our results a proof-of-
concept to design further and powered studies to con-
firm and validate this result.
Of note, the IL-32 sera levels significantly correlated
with the mPAP observed during RHC, in both iPAH and
PAH-SSc patients. These results confirmed on one the
hand the possibility that IL-32 may be a helpful
biomarker in PAH patients and, on the other hand, its
possible pathogenic role [25]. Furthermore, our results
showed that the IL-32 sera levels significantly correlated
with the sPAP evaluated with echocardiography, which
is a non-invasive and feasible assessment of suspected
PAH according to current guidelines [14, 52]. In fact,
sPAP, evaluated by echocardiography, correlates with
RHC. In this context, the need for biomarkers identify-
ing the patients’ profile at the highest risk for a poor
outcome has become of crucial interest in autoimmune
diseases [53, 54], and the correlation between IL-32 and
both sPAP and mPAP could offer a new promising
screening tool to be readily integrated in clinical prac-
tice. Furthermore, a serum determination could over-
come the limitations of echocardiography, such as
operator expertise, machine quality and patient acoustic
window [55], suggesting the possible usefulness of an in-
tegrated approach.
Additionally, we assessed the expression of IL-32 in
the skin of SSc patients. Our results showed that the
number of IL-32+ cells was significantly increased in the
skin of SSc patients, when compared with HC skin. IL-
32 was expressed in keratinocytes, vascular cells and
fibroblast cells present in the derma. It has been
reported that IL-32 may be produced by epithelial cells,
fibroblasts keratinocytes and inflammatory cells, after
stimulation with pro-inflammatory cytokines, including
interferon-γ and TNF-α [56], and all these cells are have
been frequently found to be involved in SSc pathogen-
esis [57–60]. Furthermore, higher expression of IL-32
has been reported in human epidermal keratinocytes of
atopic dermatitis, correlating with the severity of the dis-
eases [61]. Interestingly, different from the relatively
poor IL-32+ cells observed in the skin of patients with-
out PAH, the SSc skin of patients with PAH showed a
very rich IL-32+ cells, strongly confirming the very close
association between IL-32 production and vascular com-
plications leading to PAH.
In this study, we showed a correlation between the
number of IL-32+ cells and the mRSS of dcSSc pa-
tients. It is well known that the mRSS is the main
measure of outcome in dcSSc with less than 5 years
from the onset of the first symptom different from
Raynaud’s phenomenon. Thus, any biomarker, able to
correlate with mRSS, may be considered as a surro-
gate outcome measure for severity and mortality in
patients with dcSSc [37, 62, 63].
Although our study shows promising results, we are
well aware about some limitations to generalise these re-
sults, including the single-centre retrospective design
and the relatively small sample size, thus suggesting the
need of further confirmatory studies.
Conclusions
In conclusion, our study suggests that higher IL-32 sera
levels may be a useful biomarker for screening patients
with WHO group 1 PAH, before invasive assessments.
Despite future multi-centre, longitudinal studies are
needed, on a larger cohort of patients, our preliminary
results support the concept that IL-32 sera levels may
contribute to an earlier detection of SSc patients to be
referred to cardiologist for cardiac assessment, and
ultimately improving the outcome, being the early diag-
nosis of PAH crucial for initiating the proper treatment.
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